KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
This guideline cites 9 of the 58 landmark trials in our Nephrology register.
- Issued by
- KDIGO
- Year
- 2022
- Source
- Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2022;102(5S):S1–S127.doi 10.1016/j.kint.2022.06.008
The 2022 update sets out a layered treatment approach for type-2 diabetes with CKD: RAS blockade plus an SGLT2 inhibitor as the foundation, metformin where eGFR allows, a nonsteroidal MRA (finerenone) for residual albuminuric risk, and a GLP-1 receptor agonist where glycaemic targets are unmet or cardiovascular risk is high. It also reworks glycaemic monitoring in advanced CKD, where HbA1c becomes unreliable. A focused update — the KDIGO 2026 diabetes-in-CKD guideline, reworking the chapters on risk assessment, glycaemic monitoring and comprehensive pharmacotherapy — completed public review in April 2026 and is being finalised; until it is published the 2022 text remains in force. The register's supporting trials are grouped by theme below.
RAS blockade in diabetic kidney disease4
- 2013VA NEPHRON-DNephrology · CKD · RAAS blockadeIn 1,448 patients with type 2 diabetes and albuminuric CKD, dual blockade with losartan plus lisinopril did not reduce the renal composite compared with losartan alone.HR 0.8895% CI 0.70-1.12Read →
- 2001RENAAL CoreNephrology · CKD · RAAS blockadeIn 1,513 patients with type 2 diabetes and nephropathy, losartan reduced the composite of creatinine doubling, ESRD or death compared with placebo.Read →
- 2001IDNT CoreNephrology · CKD · RAAS blockadeIn 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.Read →
- 1993Captopril-DN CoreNephrology · CKD · RAAS blockadeIn 409 patients with type 1 diabetes and diabetic nephropathy, captopril reduced doubling of serum creatinine compared with placebo.HR 0.5295% CI 0.31-0.84Read →
SGLT2 inhibition2
- 2020DAPA-CKD CoreNephrology · CKD · SGLT2 inhibitorsIn 4,304 patients with CKD with or without diabetes, dapagliflozin reduced the composite of ≥50% eGFR decline, ESKD or renal/CV death compared with placebo.HR 0.6195% CI 0.51-0.72Read →
- 2019CREDENCE CoreNephrology · CKD · SGLT2 inhibitorsIn 4,401 patients with type 2 diabetes and albuminuric CKD on maximal RAS blockade, canagliflozin reduced the composite of ESKD, creatinine doubling or renal/CV death compared with placebo.HR 0.7095% CI 0.59-0.82Read →
Finerenone & nonsteroidal MRA2
- 2021FIGARO-DKDNephrology · CKD · Nonsteroidal MRAIn 7,437 patients with type 2 diabetes and CKD, finerenone reduced the cardiovascular composite compared with placebo.HR 0.8795% CI 0.76-0.98Read →
- 2020FIDELIO-DKD CoreNephrology · CKD · Nonsteroidal MRAIn 5,734 patients with type 2 diabetes and CKD, finerenone reduced the composite of kidney failure, ≥40% eGFR decline or renal death compared with placebo.HR 0.8295% CI 0.73-0.93Read →
Endothelin-receptor antagonism1
- 2019SONARNephrology · CKD · Endothelin antagonistsIn 2,648 patients with type 2 diabetes and CKD selected for response, atrasentan reduced the composite of creatinine doubling or ESKD compared with placebo.HR 0.6595% CI 0.49-0.88Read →
Published since the guideline2
- 2024FLOW CoreNephrology · CKD · GLP-1 RAIn 3,533 patients with type 2 diabetes and CKD, semaglutide reduced the composite of kidney failure, ≥50% eGFR decline or renal/CV death compared with placebo.HR 0.7695% CI 0.66-0.88Read →
- 2023EMPA-KIDNEYNephrology · CKD · SGLT2 inhibitorsIn 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.HR 0.7295% CI 0.64-0.82Read →
Cited landmark trials not yet in the register5
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 1993DCCT
Intensive glycaemic control prevented incident diabetic kidney disease in type-1 diabetes.
- 2003STENO-2
Multifactorial intervention in type-2 diabetes with microalbuminuria.
- 2017CANVAS
Canagliflozin: cardiovascular benefit with a signal for slower kidney-function decline.
- 2020VERTIS CV
Ertugliflozin — the SGLT2 class trial with the weakest cardiovascular but preserved renal signal.
- 2021AMPLITUDE-O
Efpeglenatide reduced kidney events in type-2 diabetes with CKD or high cardiovascular risk.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.